Evidence map›Paper›PMID 42604418›Full record

ArticleArchives of Iranian medicine2026

Risk Factors of Incidental Cholangiocarcinoma in Primary Sclerosing Cholangitis: A Cross-Sectional Study with ROC Curve Analysis.

Fardad Ejtehadi, Saeid Hashemieh, Ali Reza Safarpour, Sara Shojaei-Zarghani, Salar Azadnik, Alireza Shamsaeefar, Nima Rahimikashkooli

Abstract read
In one paragraph

Article in Archives of Iranian medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fardad EjtehadiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-0791-0133
Saeid HashemiehGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali Reza SafarpourGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-9880-0043
Sara Shojaei-ZarghaniColorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0001-8479-065X
Salar AzadnikInternal Medicine Department, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-6825-5312
Alireza ShamsaeefarTransplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nima RahimikashkooliInternal Medicine Department, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCholangiocarcinoma (CCA) is the most common malignancy in patients with primary sclerosing cholangitis (PSC). It is typically associated with low survival rates due to late diagnosis. This study aimed to evaluate the predictors of incidental CCA in PSC patients.

methodsIn this cross-sectional study, we included 425 patients aged 18 years or older who underwent liver transplant with a confirmed diagnosis of PSC. Demographic data, pre-transplant clinical features, and para-clinical evidence were obtained from medical records. Pathology experts examined livers removed during transplantation, and CCA was diagnosed accordingly. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were conducted to assess the risk factors for incidental CCA and the effectiveness of carbohydrate antigen 19-9 (CA 19‒9) in predicting CCA, respectively.

resultsOf the 425 included patients, 29 had PSC-CCA and 396 patients had PSC alone. According to the multivariable logistic model, CA 19‒9 (odds ratio [OR]=1.001, 95% confidence interval [CI]: 1.000‒1.001,

conclusionWe found that CA 19‒9 and weight loss are independent predictors of incidental CCA in PSC patients, and a CA 19‒9 level above 46 U/mL has relatively good predictive power for incidental CCA.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaCholangitis, SclerosingAdultCA-19-9 AntigenCross-Sectional StudiesFemaleHumansIncidental FindingsLiver TransplantationLogistic ModelsMaleMiddle AgedRisk FactorsROC CurveWeight LossCA-19-9 AntigenCA-19-9 antigenCholangiocarcinomaCholangitisSclerosing

Identifiers

PMID42604418
PMCPMC13338495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.